CTOs on the Move

Evidence CPR

www.evidence-cpr.com

 
EVIDENCE takes care of continuous education of investigators in clinical trials and takes every effort to help them keep a high level of practical knowledge of GCP (Good Clinical Practice) and other aspects of clinical trails. EVIDENCE offers GCP courses
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Nightingale Health

Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. The wide-ranging disease risk predictions provided by Nightingale consist of two interconnected factors: The extensive blood analysis technology developed by Nightingale and a large amount of data on health events. Nightingale helps people make better personal health decisions and connects the health industry to offer their services for individuals preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone. We`re a team of 60 members––a diverse bunch with interdisciplinary expertise in business, marketing, computational medicine, data science, healthcare, IT, design and more––who envisage a world that focuses on keeping people healthy rather than just treating illnesses. So, if you are looking to enable good tech that could make a real difference, Nightingale is the place to be

Oncocyte

Oncocyte’s mission is to provide tests to physicians and patients that provide answers at critical decision points during lung cancer diagnosis.

Orion Genomics

Orion Genomics is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IRX Therapeutics

IRX Therapeutics is a Farmingdale, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SignalChem Lifesciences

SignalChem Lifesciences Corporation is a privately owned biopharmaceutical company specializing in the discovery and development of kinase inhibitors as innovative therapies for cancer, inflammation and neurological diseases.   The Company has a robust kinase platform encompassing 450 kinase targets and assays for the development and commercialization of unique therapies in many diseases.   This vast resource empowers SLC’s scientists to identify novel drug candidates against kinase targets of interest.   Another key part of SLC’s kinase drug development platform is KineCore, a kinase focused small molecule library that was designed and assembled in-house.